News
Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...
Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback